Drug Database
Back to search

France· FR:61970233

SOMAVERT 30 mg, poudre et solvant pour solution injectable

A pegvisomant product containing pegvisomant, registered in France by PFIZER EUROPE MA EEIG (BELGIQUE), on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in France (Assurance maladie)ATC H01AX01

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedSOMAVERT 30 mg, poudre et solvant pou…ATCH01AX01REGISTER NO.FR:61970233PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about pegvisomantAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Pegvisomant is registered in 14 of 19 countries.

Countries holding a registration under ATC H01AX01 (pegvisomant), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 9 of them publish a price we can compare per daily dose
Search pegvisomant products by name

Pegvisomant · ATC H01AX01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pegvisomant costs, country by country.

Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Pegvisomant · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$81.23
  • ES Spain$77.80
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
PEGVISOMANT
Manufacturer
PFIZER EUROPE MA EEIG (BELGIQUE)
Country
France (FR)
ATC code
H01AX01
ATC class
Pegvisomant
Defined daily dose
10 mg, P
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400930023877
    30 flacon(s) en verre - 30 seringue(s) préremplie(s) en verre
    EUR 4.68

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

87 interactions on record for pegvisomant.

Graded by severity as the source publishes them — 87 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check pegvisomant against other medicinesHow interaction checks work

Pegvisomant · interactions on record

87 records

  • 87 moderate

Most severe, free to view

  • OpiumA07DA02moderate
  • LiraglutidA08AX02moderate
  • SemaglutidA08AX03moderate
  • Insulin (human)A10AB01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pegvisomant in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pegvisomant products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Somavert
  • Liechtenstein · Somavert
  • Norway · Somavert

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c98368c4-0e28-4997-b711-79e6bccf31c2
GET /v1/drugs/c98368c4-0e28-4997-b711-79e6bccf31c2?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "61970233",
  "date_amm": "2015-07-17",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/02/240",
  "substance": "PEGVISOMANT",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "poudre et  solvant pour solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Non"
}
API referenceMCP serverPlans

See everything about pegvisomant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console